


Amendments to the Claims

1. (Currently amended) A compound represented by the formula (I):



wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different,

R¹ is a hydrogen atom or an optionally substituted hydrocarbon group,

R² is an optionally substituted aromatic group,

Ring A is an optionally substituted benzene, an optionally substituted oxazole, an optionally substituted thiazole, an optionally substituted benzothiophen, an optionally substituted benzofuran or an optionally substituted indazolemonocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring,

X¹ is an oxygen atom or a sulfur atom,

X² is a bond, an oxygen atom or -S(O)_n- , wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, -S(O)_m-, -C(=O)-N(R³)- or -N(R³)-C(=O)- and R³ is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,

M¹, M² and M³ may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M⁴ is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or -S(O)_m-, M¹ is not a bond, (2) when Y is a bond and one of M¹ and M² is a bond, the other of M¹ and M² is neither a bond nor methylene, and (3) ~~it does not include 3-[3-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid, 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid, 5-[[4-[(1Z)-2-carboxy-2-chloroethenyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[(2-~~

methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid and 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid, ~~or a pharmaceutically acceptable salt thereof are excluded.~~

2. (Original) The compound according to the claim 1, wherein R is an optionally substituted alkyl, an optionally substituted aralkyl, an optionally substituted cycloalkyl or an optionally substituted aryl.

3. (Original) The compound according to the claim 1, wherein p is 1.

4. (Original) The compound according to the claim 1, wherein R¹ is a hydrogen atom.


5. (Original) The compound according to the claim 1, wherein R² is an optionally substituted phenyl.

6. (Currently amended) The compound according to the claim 1, wherein Ring A is an optionally substituted benzene, an optionally substituted oxazole or an optionally substituted thiazolemonocyclic aromatic ring.


7. (Currently amended) The compound according to the claim 6, wherein Ring A is an optionally substituted oxazole or an optionally substituted thiazolethe monocyclic aromatic ring is a monocyclic aromatic heterocycle.

8. (Currently amended) The compound according to the claim 6, wherein Ring A is the monocyclic aromatic ring is a an optionally substituted benzene ring or a an optionally substituted thiazole ring.

9. (Previously presented) The compound according to the claim 1, wherein the formula:



is the formula:



wherein Ring A' is an optionally further substituted benzene ring.

10. (Original) The compound according to the claim 1, wherein X¹ is an oxygen atom.

11. (Original) The compound according to the claim 1, wherein X² is a bond, an oxygen atom or a sulfur atom.

12. (Original) The compound according to the claim 1, wherein Y is an oxygen atom or a sulfur atom.

13. (Previously presented) The compound according to the claim 1, wherein Y is -C(=O)-N(R³)-, wherein R³ is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and the carbon atom is bonded to M¹, and the nitrogen atom to M².

14. (Original) The compound according to the claim 13, wherein R³ is a hydrogen atom, an optionally substituted alkyl, an optionally substituted aralkyl, an optionally substituted cycloalkyl or an optionally substituted aryl.


15. (Original) The compound according to the claim 1, wherein M¹ is an alkylene having 3 or more carbon atoms.

16. (Original) The compound according to the claim 1, wherein M¹, M² and M³ may be the same or different and are each independently a bond, an alkylene, an alkenylene or an alkynylene, and M⁴ is an alkylene, an alkenylene or an alkynylene.

17. (Currently amended) The compound according to the claim 1, wherein X² is an oxygen

atom or $-S(O)_n-$, wherein n is 0, 1 or 2 and M^3 is an optionally substituted divalent aliphatic hydrocarbon group.

18. (Currently amended) The compound according to the claim 1, wherein the formula (I) is



wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group,

R^1 is a hydrogen atom or an optionally substituted hydrocarbon group,

R^2 is an optionally substituted aromatic group,

Ring A is an optionally substituted benzene, an optionally substituted oxazole, an optionally substituted thiazole, an optionally substituted benzothiophen, an optionally substituted benzofuran or an optionally substituted indazole~~monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring~~,

X^1 is an oxygen atom or a sulfur atom,

X^2 is a bond, an oxygen atom or $-S(O)_n-$, wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, $-S(O)_m-$, $-C(=O)-N(R^3)-$ or $-N(R^3)-C(=O)-$ and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,


M^1 , M^2 and M^3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M^4 is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or $-S(O)_m-$, M^1 is not a bond, (2) when Y is a bond and one of M^1 and M^2 is a bond, the other of M^1 and M^2 is neither a bond nor methylene, and (3) ~~it does not include 3-[3-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid, 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid, 5-[[4-[(1Z)-2-carboxy-2-chloroethenyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid and 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid[,,] are excluded.~~

~~or a pharmacologically acceptable salt thereof.~~

19. (Currently amended) The compound according to the claim 18, wherein the formula (I') is



wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group,

R¹ is a hydrogen atom or an optionally substituted hydrocarbon group,

R² is an optionally substituted aromatic group,

Ring A' is an optionally further substituted benzene ring,

X¹ is an oxygen atom or a sulfur atom,

X² is a bond, an oxygen atom or -S(O)_n- , wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, -S(O)_m-, -C(=O)-N(R³)- or -N(R³)-C(=O)- and R³ is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,

M¹, M² and M³ may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M⁴ is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or -S(O)_m-, M¹ is not a bond, (2) when Y is a bond and one of M¹ and M² is a bond, the other of M¹ and M² is neither a bond nor methylene, and (3) ~~it does not include 3-[3-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid, 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid, 5-[[4-[(1Z)-2-carboxy-2-chloroethenyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid and 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid[,,]~~ are excluded.

~~or a pharmacologically acceptable salt thereof.~~

20. (Currently amended) The compound according to the claim 19, wherein X^1 is an oxygen atom, X^2 is an oxygen atom or $-S(O)_{n-1}$ wherein n is 0, 1 or 2, Y is an oxygen atom, M^1 is an optionally substituted C_{1-3} alkylene, M^2 is a bond, M^3 is a bond or an optionally substituted methylene, and M^4 is an optionally substituted methylene.

21. (Original) The compound according to the claim 20, wherein M^1 and M^3 may be the same or different and are each independently an optionally substituted methylene.


22. (Original) The compound according to the claim 19, wherein X^1 is an oxygen atom, X^2 is a bond, Y is an oxygen atom, M^1 is an optionally substituted n-propylene, M^2 and M^3 are a bond, and M^4 is an optionally substituted methylene.

23. (Currently amended) The compound according to the claim 18, wherein Ring A is an optionally substituted oxazole or an optionally substituted thiazolemonocyclic aromatic heterocycle.

24. (Currently amended) The compound according to the claim 18, wherein Ring A is an optionally substituted thiazole ring or an optionally substituted oxazole ring, X^1 is an oxygen atom, X^2 is a bond, Y is an oxygen atom or $-S(O)_{n-1}$ wherein n is 0, 1 or 2, M^1 is an optionally substituted C_{1-3} alkylene, M^2 and M^3 are a bond, and M^4 is an optionally substituted methylene.

25. (Original) The compound according to the claim 18, wherein Ring A is an optionally substituted thiazole ring, X^1 is an oxygen atom, X^2 is a bond, Y is $-S-$, M^1 is an optionally substituted methylene or an optionally substituted n-propylene, M^2 and M^3 are a bond, and M^4 is an optionally substituted methylene.

26. (Currently amended) The compound according to the claim 18, wherein the formula (I') is



wherein

R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group,

R¹ is a hydrogen atom or an optionally substituted hydrocarbon group,

R² is an optionally substituted aromatic group,

Ring A' is an optionally further substituted benzene ring,

X¹ is an oxygen atom or a sulfur atom,

X² is a bond, an oxygen atom or -S(O)_n- , wherein n is 0, 1 or 2,

Y is a bond, an oxygen atom, -S(O)_m-, -C(=O)-N(R³)- or -N(R³)-C(=O)- and R³ is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2,

M¹ is an alkylene group having 3 or more carbon atoms,

~~M¹ and M³ may be the same or different and are each independently~~is a bond or an optionally substituted divalent aliphatic hydrocarbon group, and

M⁴ is an optionally substituted divalent aliphatic hydrocarbon group,

or a pharmacologically acceptable salt thereof,

provided that (1) when Y is an oxygen atom or -S(O)_m-, M¹ is not a bond, (2) when Y is a bond M¹ is neither a bond nor methylene, and (3)~~it does not include~~ 3-[3-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid, 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid, 5-[[4-[(1Z)-2-carboxy-2-chloroethenyl]benzoyl]amino]-3-phenyl-2-thiophenecarboxylic acid, 3-[3-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]phenyl]-2-propenoic acid and 4-[(2-methyl-5-phenyl-3-furanyl)carbonyl]amino]benzeneacetic acid~~[],]~~ are excluded.

~~M¹ is an alkylene group having 3 or more carbon atoms~~

or a pharmacologically acceptable salt thereof.

27. (Currently Amended) The compound according to the claim 1, wherein R is an optionally substituted alkyl, aryl or cycloalkyl group, p is 0 or 1, R¹ is a hydrogen atom, R² is an optionally substituted phenyl group, Ring A is an optionally substituted benzene ring or an optionally substituted thiazole ring, X¹ is an oxygen atom, X² is a bond or an oxygen atom, Y is an oxygen atom or -C(=O)-N(R³)-, wherein R³ is a hydrogen atom, alkyl or aralkyl, and the carbon atom is bonded to M¹, and the nitrogen atom to M², M¹, M² and M³ may be the same or different and are each independently a bond or alkylene, and M⁴ is alkylene.

28. (Currently amended) The compound according to the claim 1, wherein R is an optionally substituted alkyl, aryl or cycloalkyl group, p is 0 or 1, R¹ is a hydrogen atom, R² is an optionally substituted phenyl group, Ring A is an optionally substituted benzene ring or an optionally substituted thiazole ring, X¹ is an oxygen atom, X² is a bond or -S(O)_n-, wherein n is 0, 1 or 2, Y is an oxygen atom or -C(=O)-N(R³)-, wherein R³ is a hydrogen atom, alkyl or aralkyl, and the carbon atom is bonded to M¹, and the nitrogen atom to M², M¹, M² and M³ may be the same or different and are each independently a bond or alkylene, and M⁴ is alkylene.

29. (Original) A prodrug of the compound according to the claim 1.

30. (Previously presented) A pharmaceutical medicine composition comprising the compound according to the claim 1 or a prodrug thereof and a pharmaceutically acceptable carrier, excipient or diluent.

31. (Original) An agent of regulating nuclear receptor PPAR comprising the compound according to the claim 1 or a prodrug thereof.

32. (Cancelled)

33. (Currently amended) The agent according to the claim 31, which is a therapeutic agent for
~~The prophylactic or therapeutic agent according to the claim 32, wherein the nuclear receptor PPAR related diseases are~~ lipid metabolism abnormality or sequelae thereof, arteriosclerotic disease or sequelae thereof, diabetes mellitus, or impaired glucose tolerance.

34. (Original) The medicine according to the claim 30, which is an agent of raising high-density lipoprotein cholesterol, an agent of lowering triglyceride, an agent of lowering low-density lipoprotein cholesterol or an agent of suppressing progress of arteriosclerotic plaque.

35. (Original) An agent of regulating GPR40 receptor function comprising the compound according to the claim 1 or a prodrug thereof.

36. (Original) The agent according to the claim 35, which is an agent of regulating insulin secretion, an agent of lowering blood glucose or an agent of protecting pancreatic β cell.

37. (Currently amended) The agent according to the claim 35, which is a ~~prophylactic or~~ therapeutic agent for diabetes mellitus, glucose intolerance, ~~ketosis, acidosis, diabetic~~ neuropathy, diabetic nephropathy, diabetic retinopathy, hyperlipidemia, ~~sexual dysfunction, cutaneous diseases, arthropathy, osteopenia, arteriosclerosis, thrombotic diseases, dyspepsia, memory and learning disorders, obesity, hypoglycaemia, hypertension, edema, insulin resistant syndrome, unstable diabetes mellitus, lipotrophy, or insulin allergy, insulinoma, lipotoxicity or cancer.~~

38-51. (Cancelled)